Skip to main content
CELC
NASDAQ Industrial Applications And Services

Celcuity Launches REVTORPYK Commercially in the U.S. for HR+/HER2- Advanced Breast Cancer

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$79
Mkt Cap
$3.786B
52W Low
$44.42
52W High
$151.02
52W Position info
78% above low
Off High info
48% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

CELC sits 78% above its 52-week low of $44.42.

Summary

Celcuity announced that REVTORPYK (gedatolisib) is now commercially available in the U.S. for eligible patients with HR+/HER2- advanced breast cancer without a PIK3CA mutation, marking the company's first commercial product launch.


Key Events · Product Development and Regulatory · CELC

  • REVTORPYK Commercial Launch

    REVTORPYK (gedatolisib) is now commercially available in the U.S. for HR+/HER2- advanced breast cancer without a PIK3CA mutation, following FDA approval on July 14, 2026.

  • First Commercial Product

    This is Celcuity's first FDA-approved and commercially available product, transitioning the company from clinical-stage to commercial-stage.

  • Patient Support Program Launched

    REVTORPYK Support Services program launched to provide financial assistance, insurance coverage support, and treatment enrollment resources for physicians and eligible patients.

  • Clinical Differentiation

    REVTORPYK is the first and only FDA-approved therapy inhibiting all class I PI3K isoforms and mTORC1/mTORC2, with Phase 3 data showing 76% and 67% risk reduction for triplet and doublet regimens respectively.


Analysis · CELC · Industrial Applications And Services

REVTORPYK, Celcuity's first FDA-approved drug, is now commercially available in the United States. This marks the company's transition from clinical-stage to commercial-stage, with revenue generation now possible. The launch follows the July 14, 2026 FDA approval and includes a patient support program to facilitate access and reimbursement. For a company with a $3.8 billion market cap and $754 million in cash, successful commercialization is the key milestone investors have been waiting for.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CELC was trading at $79.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $3.8B. The 52-week trading range was $44.42 to $151.02. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CELC - Latest Insights

CELC
Nov 09, 2026, 8:30 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $66.32
Real-time Price: $64.37 info
Change: -$1.95 (-3%) info
Market Cap: $3.162B info
CELC
Nov 05, 2026, 5:15 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $64.04
Real-time Price: $64.37 info
Change: +$0.330 (+0.52%) info
Market Cap: $3.162B info
CELC
Nov 05, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $64.04
Real-time Price: $64.37 info
Change: +$0.330 (+0.52%) info
Market Cap: $3.162B info
CELC
Nov 05, 2026, 4:02 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $64.04
Real-time Price: $64.37 info
Change: +$0.330 (+0.52%) info
Market Cap: $3.162B info
CELC
Aug 26, 2026, 8:35 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $91.00
Real-time Price: $64.37 info
Change: -$26.63 (-29%) info
Market Cap: $3.162B info